Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed.

摘要: Background: Treatment with oxaliplatin plus raltitrexed has demonstrated an encouraging therapeutic index in patients advanced colorectal cancer and malignant pleural mesothelioma. The aim of this multi-institutional study was to determine the antitumor potential combination metastatic gastric failing prior palliative first-line chemotherapy, reconfirm its favorable toxicity profile. Patients Methods: 21 cancer, who progressed while on or within 6 months after discontinuing participated study. They received 3,0 mg/m² 130 both given intravenously day 1 every 3 weeks. Results: One patient achieved a partial response, had stable disease, 14 progressed. Median progression-free overall survival from onset salvage chemotherapy 2.0 4.5 months, respectively. Hematologic adverse reactions, specifically neutropenia anemia were common, though generally mild moderate only experiencing grade 3/4 toxicity. most frequent non-hematologic events included nausea/emesis, asthenia, transient elevation liver functional parameters, again symptoms occurring minority patients. Conclusion: Despite reproducibility profile + raltitrexed, our data suggest that regimen no substantial activity progressive, chemotherapeutically pretreated cancer.